There is limited research on the effects of the combination of PD-1/PD-L1 inhibitors and anti-vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) drugs on tumor immune cells. Here, CD274 is linked to neoplasm.